PharmaDispatch - PharmaDispatch

Latest News
PEFO confirms MA secured ATAGI fee delay

The Pre-election Economic and Fiscal Outlook has confirmed the delay in the implementation of the new $300,000 fee for vaccine submissions to ATAGI.

Latest News 'Right to Trial' in blood cancers-a limited version of Trump's 'Right to Try' April 18, 2019
Labor's $20 million commitment to a 'Right to Trial' program sounds very similar to US President Donald Trump's 'Right to Try' initiative.
Latest News MA starts communication on 'principles' Code April 18, 2019
The new Code is proposed to be substantially shorter than the current 90-page edition - potentially around 30 pages - and it will focus on 'principles' rather than detailed and explicitly worded provisions.
Latest News Pfizer goes red for World Haemophilia Day April 18, 2019
“The theme of World Haemophilia Day this year is to ‘reach out and connect with your community’ and given we are new to the CBD we thought we could make a special effort to show our support,” said Emma Bonser, Pfizer’s Rare Diseases Lead.
Labor commits to 'early access' trials April 17, 2019
"We know that the fastest way to get access to the latest drugs and treatments available in the world is through clinical trials. This is also the only way to develop the evidence needed to list treatments on the PBS and MBS – providing access for all," said Labor leader Bill Shorten.
Latest News Jacinda Ardern: 'Work to be done' on PHARMAC April 17, 2019
"There are elements of our PHARMAC model that are just exemplary. However, for early access, I do think there is work to be done," said Prime Minister Jacinda Ardern.
'MyPharmaSpace' Pfizer and J&J partner to support LGBTQI colleagues April 17, 2019
More than 90 people from across the pharmaceutical industry will gather this morning at Pfizer’s Barrack Place office in Sydney for a breakfast to discuss workplace inclusion and support of LGBTQI colleagues.
Latest News Data on out-of-pocket costs paints a very mixed picture April 16, 2019
Around 40 per cent of the $29 billion identified as consumer out-pocket-costs was spent on a combination of non-benefit medicines and 'other' health professionals.
Latest News AusBiotech laments 'wearisome' uncertainty over fate of R&D tax incentive April 17, 2019
AusBiotech has described as "wearisome" the ongoing uncertainty over the fate of the Research and Development Tax Initiative program.
Latest News New study reveals positive news for BI's Pradaxa April 17, 2019
The latest study of real-world data for PRADAXA (dabigatran) has delivered positive news for Boehringer Ingelheim and for patients with non-valvular atrial fibrillation.
Latest News More intervention may be needed on gene therapies April 16, 2019
Novartis has the existing organisational capacity to support the Australian commercialisation of a gene therapy like KYMRIAH - and it was still very hard - many companies developing similar treatments have virtually no presence in Australia.
Latest News Hepatitis Australia: Need for action as the task 'just got more difficult' April 16, 2019
Hepatitis Australia has expressed understanding, disappointment and concern over MSD's decision to cease all promotion of its direct-acting antiviral for hepatitis C, ZEPATIER (grazoprevir and elbasvir).
Latest News Making the case for 'US-Australia PBS Plus' April 16, 2019
What could the EU and UK ask for when it comes to PBS process? What about an update or enhancement to the provisions included in the US-Australia agreement?

News of the Day

Latest Video

Most Read

New Stories